Compare Automatic Data Processing Inc (ADP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Automatic Data Processing Inc trades at $267.1 (market cap $107.69B), while Vertex Pharmaceuticals Incorporated trades at $528.16 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Automatic Data Processing Inc pays a 2.51% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ADP | VRTX | |
|---|---|---|
Market Cap | $107.69B | $134.25B |
Sector | Industrials | Health |
52-Week High | $309.03 | $529.65 |
52-Week Low | $188.79 | $376.62 |
Enterprise Value | $108.73B | $128.37B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $273.68, up 0.87% today, near its consensus price target of $280.50. The stock shows bullish technical signals with strong moving averages and support at $270. Recent quarterly earnings consistently beat estimates, with Q2 2026 EPS of $2.64 surpassing the $2.59 forecast. Revenue growth is steady, reaching $20.56 billion in 2025, with a net income margin of 20.11% and robust ROE of 72.24%.
Outlook remains positive given earnings momentum and dividend stability, but high valuation multiples (P/E 24.78, P/S 4.98) pose risks if growth slows. Analyst sentiment is mixed with 63.89% hold ratings, reflecting caution amid elevated prices. Key risks include labor market sensitivity and competitive pressures in payroll processing.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
